Pfizer picks up Brazil's Teuto in $240M deal

Pfizer will pay $240 million for a 40 percent stake in Brazil's Laboratorio Teuto Brasileiro, a generics specialist, as it expands further in emerging markets. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.